De Luca L, Rubboli A, Bolognese L, et al. - In this non-interventional, prospective, nationwide study, researchers sought to evaluate current management of patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) undergoing coronary stenting. This investigation was carried out at 76 private or public cardiology centres in Italy. Five hundred ninety-eight consecutive patients were registered over a 12-month period: 48.8% with AF at hospital admission and 51.2% developing AF during hospitalisation. TAT was still the antithrombotic strategy of choice in this contemporary registry of patients with ACS with AF treated with coronary stents, DAT was reserved for high bleeding risk, and DAPT was primarily administered during hospitalization in those who developed AF.